Table 2. IHC scores of dMMR and pMMR patients.

	IHC score	dMMR	pMMR	p
PD-1 (TIL and stroma)	0	1 (3.4%)	3 (3.6%)	0.003**
	1	1 (3.4%)	15 (17.9%)
	2	4 (13.8%)	31 (36.9%)
	3	23 (79.3%)	35 (41.7%)
PD-1 (invasive front)	0	0 (0%)	1 (1.2%)	0.003**
	1	1 (3.4%)	11 (13.1%)
	2	5 (17.2%)	37 (44.0%)
	3	23 (79.3%)	35 (41.7%)
PD-L1(tumor cells)	(-)	19 (65.5%)	54 (64.3%)	0.905
	(+)	10 (34.5%)	30 (35.7%)
PD-L1 percent(immune cell infiltrates)	<60%	9 (31.0%)	35 (41.7%)	0.311
	≥60%	20 (69.0%)	49 (58.3%)
	<70%	11 (37.9%)	48 (57.1%)	0.074
	≥70%	18 (62.1%)	36 (42.9%)
	<80%	14 (48.3%)	65 (77.4%)	0.003**
	≥80%	15 (51.7%)	19 (22.6%)
PD-L1 intensity(immune cell infiltrates)	0	0 (0%)	1 (1.2%)	0.964
	1	4 (13.8%)	12 (14.3%)
	2	19 (65.5%)	51 (60.7%)
	3	6 (20.7%)	20 (23.8%)
AIS	0-50	4 (13.8%)	11 (13.1%)	0.155
	60-100	6 (20.7%)	23 (27.4%)
	110-200	13 (44.8%)	41 (48.9%)
	210-300	6 (20.7%)	9 (10.7%)
IDO	low	13 (44.8%)	53 (63.1%)	0.026*
	high	16 (55.2%)	31 (36.9%)
CD8 (TIL and stroma)	(-)	6 (20.7%)	9 (10.7%)	0.017*
	(+)	12 (41.4%)	52 (61.9%)
	(++)	4 (13.8%)	18 (21.4%)
	(+++)	7 (24.1%)	5 (6.0%)
CD8 (invasive front)	(-)	0 (0%)	0 (0%)	0.038*
	(+)	9 (31%)	30 (35.7%)
	(++)	5 (17.2%)	31 (36.9%)
	(+++)	15 (51.7%)	23 (27.4%)